Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDi Cosimo, Serena
dc.contributor.authorPorcu, Luca
dc.contributor.authorAgbor-tarh, Dominique
dc.contributor.authorCinieri, Saverio
dc.contributor.authorFranzoi, Maria Alice
dc.contributor.authorDe Santis, Maria Carmen
dc.contributor.authorSaura Manich, Cristina
dc.date.accessioned2021-09-10T10:04:01Z
dc.date.available2021-09-10T10:04:01Z
dc.date.issued2020-10-27
dc.identifier.citationDi Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res. 2020 Oct 27;22:115.
dc.identifier.issn1465-542X
dc.identifier.urihttp://hdl.handle.net/11351/6297
dc.descriptionÍndex de massa corporal; Càncer de mama HER2-positiu; Tractament neoadjuvant
dc.description.sponsorshipThe NeoALTTO study was sponsored by GlaxoSmithKline from its inception until November 30, 2015, and by Novartis since then. Lapatinib is an asset of Novartis AG as of March 2, 2015. Funding sources had no involvement in the study design, data collection, analysis and interpretation, writing of the report, and decision to submit the article for publication.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesBreast Cancer Research;22
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectObesitat - Fisiologia patològica
dc.subject.meshBreast Neoplasms
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshOverweight
dc.subject.mesh/physiopathology
dc.titleEffect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13058-020-01356-w
dc.subject.decsneoplasias de la mama
dc.subject.decstratamiento neoadyuvante
dc.subject.decssobrepeso
dc.subject.decs/fisiopatología
dc.relation.publishversionhttps://doi.org/10.1186/s13058-020-01356-w
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Di Cosimo S] Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, via G.A. Amadeo 42, 20133 Milano, Italy. [Porcu L] Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. [Agbor-tarh D] Frontier Science (Scotland) Ltd, Kincraig, UK. [Cinieri S] San Antonio Perrino Hospital, Brindisi, Italy. [Franzoi MA] Institut Jules Bordet and l’Universitè Libre de Bruxelles (U.LB), Brussels, Belgium. [De Santis MC] Radiation Oncology, Fondazione IRSCCS Istituto Nazionale dei Tumori, Milano, Italy. [Saura C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid33109233
dc.identifier.wos000589613500004
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple